Podcasts about high drug prices

Send us a textReady to unravel the mystery behind sky-high drug prices? Join Dr. Michael Koren, a top-tier cardiologist and medical researcher, as he dissects the factors driving the pharmaceutical industry's steep costs. From the firm grip of patent protection to the complex role of pharmacy benefit managers (PBMs) in price negotiations, Dr. Koren illuminates the multifaceted challenges of making medications more affordable. Recording Date: September 23, 2024Be a part of advancing science by participating in clinical research.Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

The 30-year fixed-rate mortgage is as American as apple pie. But it wasn’t always this way, and it’s putting the housing market in a tough spot lately.  A substantial amount of homeowners with low-rate mortgages are choosing to stay put in their homes rather than selling and buying a new one at higher rates. It’s created what’s known as a lock-in effect. On the show today, Andra Ghent, professor of finance at the University of Utah, explains how a 30-year fixed-rate mortgage became the norm in the United States, why it’s now putting the housing market in a bind, and how our mortgage system perpetuates inequality. Plus, could the Danish mortgage model work here? Then, we’ll get into why the Federal Trade Commission is eyeing pharmacy benefit managers, the third-party companies that negotiate drug prices between health insurance providers and drugmakers. And, an editor at The Points Guy shares the story of a travel lesson learned. Here’s everything we talked about today: “Why do we have a 30-year mortgage, anyway?” from Marketplace “A Huge Number of Homeowners Have Mortgage Rates Too Good to Give Up” from The New York Times “A 30-Year Trap: The Problem With America's Weird Mortgages” from The New York Times “Denmark’s genius housing fix” from Business Insider “Homeowners Don't Want to Sell, So the Market for Brand-New Homes Is Booming” from The Wall Street Journal “FTC Releases Interim Staff Report on Prescription Drug Middlemen” from the Federal Trade Commision “F.T.C. Slams Middlemen for High Drug Prices, Reversing Hands-Off Approach” from The New York Times “State Pharmacy Benefit Manager Legislation” from the National Academy for State Health Policy “Prescription Drugs: Selected States’ Regulation of Pharmacy Benefit Managers” from the U.S. Government Accountability Office “Fed Chair Powell talks up progress on inflation but says rate cuts not imminent yet” from CNN Business “Software and social media to grab Congress’ attention” from Marketplace We love to hear from you. Send your questions and comments to makemesmart@marketplace.org or leave us a voicemail at 508-U-B-SMART.

The 30-year fixed-rate mortgage is as American as apple pie. But it wasn’t always this way, and it’s putting the housing market in a tough spot lately.  A substantial amount of homeowners with low-rate mortgages are choosing to stay put in their homes rather than selling and buying a new one at higher rates. It’s created what’s known as a lock-in effect. On the show today, Andra Ghent, professor of finance at the University of Utah, explains how a 30-year fixed-rate mortgage became the norm in the United States, why it’s now putting the housing market in a bind, and how our mortgage system perpetuates inequality. Plus, could the Danish mortgage model work here? Then, we’ll get into why the Federal Trade Commission is eyeing pharmacy benefit managers, the third-party companies that negotiate drug prices between health insurance providers and drugmakers. And, an editor at The Points Guy shares the story of a travel lesson learned. Here’s everything we talked about today: “Why do we have a 30-year mortgage, anyway?” from Marketplace “A Huge Number of Homeowners Have Mortgage Rates Too Good to Give Up” from The New York Times “A 30-Year Trap: The Problem With America's Weird Mortgages” from The New York Times “Denmark’s genius housing fix” from Business Insider “Homeowners Don't Want to Sell, So the Market for Brand-New Homes Is Booming” from The Wall Street Journal “FTC Releases Interim Staff Report on Prescription Drug Middlemen” from the Federal Trade Commision “F.T.C. Slams Middlemen for High Drug Prices, Reversing Hands-Off Approach” from The New York Times “State Pharmacy Benefit Manager Legislation” from the National Academy for State Health Policy “Prescription Drugs: Selected States’ Regulation of Pharmacy Benefit Managers” from the U.S. Government Accountability Office “Fed Chair Powell talks up progress on inflation but says rate cuts not imminent yet” from CNN Business “Software and social media to grab Congress’ attention” from Marketplace We love to hear from you. Send your questions and comments to makemesmart@marketplace.org or leave us a voicemail at 508-U-B-SMART.

The 30-year fixed-rate mortgage is as American as apple pie. But it wasn’t always this way, and it’s putting the housing market in a tough spot lately.  A substantial amount of homeowners with low-rate mortgages are choosing to stay put in their homes rather than selling and buying a new one at higher rates. It’s created what’s known as a lock-in effect. On the show today, Andra Ghent, professor of finance at the University of Utah, explains how a 30-year fixed-rate mortgage became the norm in the United States, why it’s now putting the housing market in a bind, and how our mortgage system perpetuates inequality. Plus, could the Danish mortgage model work here? Then, we’ll get into why the Federal Trade Commission is eyeing pharmacy benefit managers, the third-party companies that negotiate drug prices between health insurance providers and drugmakers. And, an editor at The Points Guy shares the story of a travel lesson learned. Here’s everything we talked about today: “Why do we have a 30-year mortgage, anyway?” from Marketplace “A Huge Number of Homeowners Have Mortgage Rates Too Good to Give Up” from The New York Times “A 30-Year Trap: The Problem With America's Weird Mortgages” from The New York Times “Denmark’s genius housing fix” from Business Insider “Homeowners Don't Want to Sell, So the Market for Brand-New Homes Is Booming” from The Wall Street Journal “FTC Releases Interim Staff Report on Prescription Drug Middlemen” from the Federal Trade Commision “F.T.C. Slams Middlemen for High Drug Prices, Reversing Hands-Off Approach” from The New York Times “State Pharmacy Benefit Manager Legislation” from the National Academy for State Health Policy “Prescription Drugs: Selected States’ Regulation of Pharmacy Benefit Managers” from the U.S. Government Accountability Office “Fed Chair Powell talks up progress on inflation but says rate cuts not imminent yet” from CNN Business “Software and social media to grab Congress’ attention” from Marketplace We love to hear from you. Send your questions and comments to makemesmart@marketplace.org or leave us a voicemail at 508-U-B-SMART.

This week the hosts examine research that shows high drug prices are not justified by industry's research and development spending, and they discuss research showing COVID-19 vaccinations in pregnancy protects infants. Plus, they speak with guest author Maya Kaimal about her recipe for Coconut Noodle Soup.

This week the hosts examine research that shows high drug prices are not justified by industry's research and development spending, and they discuss research showing COVID-19 vaccinations in pregnancy protects infants. Plus, they speak with guest author Maya Kaimal about her recipe for Coconut Noodle Soup.

Drug prices are top of mind for numerous patients, legislators, policy experts, and antitrust enforcers these days. But what role do pharmacy benefit managers (PBMs) play in determining the price and availability of drugs at the pharmacy counter, and why do PBMs find themselves in the middle of an FTC market study looking into their business practices? Join Alicia Downey and Jeny Maier as they talk with Dr. Erin Trish, an economist and health policy expert, about the evolution of PBMs and the current antitrust inquiries they are facing. Listen to this episode if you want to learn more about what goes into the price that you pay for your prescription. With special guest: Dr. Erin Trish, Co-Director, Schaeffer Center for Health Policy & Economics, University of Southern California Related Links: USC Schaeffer Center Research on the Pharmaceutical Distribution Chain USC Schaeffer Center Public Comments to FTC on PBMs Who Is Really Driving Up Insulin Costs? (April 18, 2022) Testimony Before the U.S. Senate Committee on Commerce, Science, & Transportation on Bringing Transparency and Accountability to Pharmacy Benefit Managers (February 16, 2023) Livestream Video of Senate Committee Hearing Hosted by: Alicia Downey, Downey Law LLC and Jeny Maier, Axinn, Veltrop & Harkrider LLP

This week the hosts examine research that shows high drug prices are not justified by industry's research and development spending, and they discuss research showing COVID-19 vaccinations in pregnancy protects infants. Plus, they speak with guest author Maya Kaimal about her recipe for Coconut Noodle Soup.

This week the hosts examine research that shows high drug prices are not justified by industry's research and development spending, and they discuss research showing COVID-19 vaccinations in pregnancy protects infants. Plus, they speak with guest author Maya Kaimal about her recipe for Coconut Noodle Soup.

Dr. James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.C. Robinson. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform. N Engl J Med 2021;385:2017-2019.

Many medical experts predict that biosimilars are essential to the future of healthcare. What are they and how will they shake up the pharmaceuticals industry? John and David have the answers.Visit us at www.caretalkpodcast.comWatch this episode on YouTube: https://youtu.be/MTCvnvePGI0Follow us on the Health Podcast Network: https://bit.ly/3Glciwj#healthcarebusiness #healthcarepolicy #health #biosimilars #caretalk

Millions of Americans cannot afford the medications they’ve been prescribed. Many skip doses, split pills or don’t fill prescriptions at all as a result, with sometimes even fatal consequences. But doctors are often unable to consider cost very well in prescribing, as the same drug often costs patients vastly different amounts due to insurance differences. Experts discuss the problem and what patients can do to save.

Expert health services researcher Dr. Stacie Dusetzina discusses how a $400 drug really costs $12, Biden's healthcare plan, bipartisan bill proposals, capping out-of-pocket costs, international reference pricing, value-based pricing, and how the COVID-19 vaccine will transform future drug pricing with Klara.

Though the FDA has a big role to play in the reason that prescription drug prices in the United States is so high, they aren't the only ones to blame.  This is day 3 of A Costly Cure: Struggling with soaring prescription prices our look into the rising cost of prescription drugs. 

If you had a rare disease and the only drug that could help you suddenly shot up in price how would you feel? What if your health service or insurer decided it was too expensive and they wouldn’t fund it any more? This is the problem facing some patients in the Netherlands. In order to encourage pharmaceutical companies to invest in developing drugs for rare diseases, the EU allows them to have a 10-year monopoly. The number of these drugs has risen as a result, but the way the rules are written has created a problem. Pharma companies have been able to re-register old drugs that were used for other diseases and then, with their legal monopoly, raise the price significantly. While some countries might accept the price rise, the Netherlands hasn’t, and small-scale pharmacists there are stepping in. They’re making small quantities of some of the drugs themselves and giving them to patients, at a fraction of the cost. People Fixing the World hears from the patients, pharmacists and big pharma companies who are trying to find a way forward. Reporter: Charlotte Horn (Photo Credit: Marleen Kemper)

The Senate recently held a hearing with high level executives with the Big Pharmaceutical companies relating to how much they charge for their drugs and why it is so much. I answer here why they can, the Government - through the FDA- enforces monopoly drug markets. For all links and references mentioned in the podcast, please visit my youtube link here: https://www.youtube.com/watch?v=ZiLsSs2buBA --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/ericjgoveconchurchcomm/message Support this podcast: https://anchor.fm/ericjgoveconchurchcomm/support

http://traffic.libsyn.com/radiohealthjournal/RHJ__19-18A.mp3 Dr. Stacie Dusetzina, Associate Professor of Health Policy at Vanderbilt University School of Medicine has learned that 1 in 4 people have trouble filling their prescription. According to Dusetzina, people with chronic conditions, like cancer, have a greater risk of running into financial obstacles. One cancer patient is taking a stand against the financial burden of disease. Millions of Americans cannot afford the medications they’ve been prescribed. Many skip doses, split pills, trade pills with friends and family, or don’t fill prescriptions at all as a result––with sometimes even fatal consequences. Dr. Stacie Dusetzina, Associate Professor of Health Policy at Vanderbilt University School of Medicine has learned that 1 in 4 people have trouble filling their prescription. According to Dusetzina, people with chronic conditions, like cancer, have a greater risk of running into financial obstacles. One cancer patient is taking a stand against the financial burden of disease. David Mitchell, a 68-year-old living with multiple myeloma is the founder of Patients for Affordable Drugs. The two drugs that make Mitchell’s rare form of cancer treatable cost $325,000 a year. For Mitchell, the only reason his drugs are affordable are thanks to insurance and the fact that his drugs are infused rather than pills. Mitchell is seemingly luck with his insurance and form of treatment. A study in the Annals of Internal Medicine reveals that up to 30% of prescriptions are never filled, with cost likely a contributing factor. Some people can’t afford $50 a month for treatment, Dusetzina says, and the price can hinder people from taking the full prescription. Dusetzina believes, splitting up drug doses may be worse than taking none at all. Cutting medication could lead to drug resistance––an outcome potentially worse than taking no drug at all. In particular, Dusetzina says that patients who are rationing insulin are threatening their own lives to a sometimes fatal extent. And it is not just the illness but also the stress that comes from the price of the drugs that can make someone worse, according to Mitchell. A solution the CDC has begun to work on to combat the pricing out drug dilemma would involve a system where a physician takes a patient’s insurance card and in real time knows the cost of the drug they are about to prescribe. This would be extremely beneficial for financial drug adjustment. According to the CDC, 60% of those who are uninsured have not asked their pharmacist or physician if there are cheaper treatment options––options that could be just as life-saving as the drugs themselves. Guests: David Mitchell, cancer patient, founder and President, Patients for Affordable Drugs Dr. Stacie Dusetzina, Associate Professor of Health Policy, Vanderbilt University Links for more information: Patients for Affordable Drugs – Our Team Stacie B. Dusetzina, Ph.D. – Vanderbilt University Medical Center

Contagious obstruction: help Cummings fight high drug prices; Mueller facts vs Barr‘s ‘spin cycle’   Congressman Cummings, chairman of the House Oversight and Reform Committee is trying to lower drug prices but is being thwarted by republicans Jim Jordan and Mark Meadows. Is it any wonder when drug companies gave 42% more money to House Republicans than Democrats in 2018? https://www.bloomberg.com/quicktake/drug-prices Link to ‘Open Secrets.org who track the money.. https://www.opensecrets.org/industries/summary.php?ind=H04&cycle=2018&recipdetail=A&sortorder=U   Barr hits the ‘spin cycle’ as fast as he can to try and wash away the lies, collusion and obstruction   Some strange stories about... a haunted grocery store?  

Every week, The American Journal of Managed Care® (AJMC®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care news included courts rejecting multiple health initiatives from the Trump administration; Congress heard more about rising insulin prices; a new agreement seeks standards for reporting social determinants of health. Read more about the stories in this podcast: Federal Judge Strikes Down Medicaid Work Rules in Kentucky, Arkansas: https://www.ajmc.com/newsroom/federal-judge-strikes-down-medicaid-work-rules-in-kentucky-arkansas Judge Rules Trump's DOL Tried to Create "End Run" Around ACA With Association Health Plans: https://www.ajmc.com/newsroom/judge-rules-trumps-dol-tried-to-create-end-run-around-aca-with-association-health-plans Healthcare Availability, Affordability Most Pressing Worry, Gallup Poll Says: https://www.ajmc.com/newsroom/healthcare-availability-affordability-most-pressing-worry-gallup-poll-says House Subcommittee Hears About Impact of Rising Insulin Prices: https://www.ajmc.com/newsroom/house-subcommittee-hears-about-impact-of-rising-insulin-prices House Subcommittee Hears Insulin Concerns as FDA Advances Biosimilar Transition: https://www.centerforbiosimilars.com/news/house-subcommittee-hears-insulin-concerns-as-fda-advances-biosimilar-transition Senate Committee Discusses the Burden of High Drug Prices and Potential Solutions: https://www.ajmc.com/newsroom/senate-committee-discusses-the-burden-of-high-drug-prices-and-potential-solutions AMA, UnitedHealthcare Announce Collaboration to Better Identify, Address SDOH Through Data: https://www.ajmc.com/newsroom/ama-unitedhealthcare-announce-collaboration-to-better-identify-address-sdoh-through-data Louisiana Chooses Asegua to Partner for "Netflix" Subscription Model for HCV Treatment: https://www.ajmc.com/focus-of-the-week/louisiana-chooses-asegua-to-partner-for-netflix-subscription-model-for-hcv-treatment Evidence-Based Diabetes Management—March 2019: https://www.ajmc.com/journals/evidence-based-diabetes-management/2019/march-2019 Three Years After Advocates Report Flaws, Medicare Diabetes Test Strip Bidding Program Nears Collapse: https://www.ajmc.com/journals/evidence-based-diabetes-management/2019/march-2019/three-years-after-advocates-report-flaws-medicare-diabetes-test-strip-bidding-program-nears-collapse From the Editor-in-Chief: Halt the Glucose Test Strip Bidding Program Until It Can Be Fixed: https://www.ajmc.com/journals/evidence-based-diabetes-management/2019/march-2019/from-the-editorinchief-halt-the-glucose-test-strip-bidding-program-until-it-can-be-fixed

Every week, The American Journal of Managed Care® (AJMC®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care news included pharmaceutical executives appearing before a Senate drug pricing hearing; HHS finalizing a Title X rule change; and an analysis that found travel and wait times for healthcare services come with a high price. Read more about the stories in this podcast: Senate Committee Discusses the Burden of High Drug Prices and Potential Solutions: https://www.ajmc.com/newsroom/senate-committee-discusses-the-burden-of-high-drug-prices-and-potential-solutions Pharma Executives Call for Reforms to Medicare, Rebate System in Senate Hearing: https://www.ajmc.com/focus-of-the-week/pharma-executives-call-on-reforms-to-medicare-rebate-system-in-senate-hearing HHS Rule Bars Clinics That Perform Abortion, Make Referrals From Receiving Title X Funds: https://www.ajmc.com/newsroom/hhs-rule-bars-clinics-that-perform-abortion-make-referrals-from-receiving-title-x-funds HPV Vaccines Cut Cervical Cancer Rates, Study Shows: https://www.ajmc.com/newsroom/hpv-vaccination-safeguarding-against-cervical-cancer Travel, Wait Times for Healthcare Services Cost $89 Billion Annually: https://www.ajmc.com/focus-of-the-week/travel-wait-times-for-healthcare-services-cost-89-billion-annually American Academy of Allergy, Asthma and Immunology 2019: https://www.ajmc.com/conferences/aaaai-2019

At a hearing this week, Senators from both parties grilled executives from major pharmaceutical companies about skyrocketing drug prices. AARP’s Leigh Purvis shares how this impacts us all and why Congress needs to act now.

Every week, The American Journal of Managed Care® (AJMC®) recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care news included House and Senate hearings on the cost of prescription drugs; a study finding patients with diabetes can be safely switched to cheaper insulin; and the first non-chemotherapy combination being approved for the treatment of chronic lymphocytic leukemia. Read more about the stories in this podcast: Senate Committee Discusses the Burden of High Drug Prices and Potential Solutions: https://www.ajmc.com/newsroom/senate-committee-discusses-the-burden-of-high-drug-prices-and-potential-solutions Medicare Patients With Type 2 Diabetes Safely Switched From Analog to Human Insulin, JAMA Study Finds: https://www.ajmc.com/newsroom/medicare-patients-with-type-2-diabetes-safely-switched-from-analog-to-human-insulin-ijamai-study-finds FDA Approves Ibrutinib Combination as Frontline Treatment for CLL: https://www.ajmc.com/newsroom/fda-approves-ibrutinib-combination-as-frontline-treatment-for-cll What Do Americans Think About Medicare for All? It Depends on What They Hear: https://www.ajmc.com/focus-of-the-week/what-do-americans-think-about-medicare-for-all-it-depends-on-what-they-hear Congress Doubles Down on High Drug Prices, but Is It More Talk Than Action? https://www.ajmc.com/focus-of-the-week/congress-doubles-down-on-high-drug-prices-but-is-it-more-talk-than-action The Drug Price Iceberg: More Than Meets the Eye: https://www.ajmc.com/journals/issue/2019/2019-vol25-n2/the-drug-price-iceberg-more-than-meets-the-eye

Thom analyses the corruption of the pharmaceutical business as drug companies flaunt ethics and do anything for money. Listeners call in with their often life and death experiences.With the approach of what may be a historically damaging hurricane, Thom examines the willful blindness of climate change by governments under the sway of Republican greed. Davis Hammet, president of activist group Loud Light details voter suppression ongoing in Kris Kobach's Kansas, and what can be done about it.And, Ellen Rattner drops in from Talk Media News with the most interesting headlines.

The White House laid out measures to tackle high list prices for drugs last week, hitting out at "freeloading" foreign countries that benefit from US pharmaceutical research. The FT's David Crow explains. See acast.com/privacy for privacy and opt-out information.

Kenneth Frazier, the CEO of the pharmaceutical company known as MSD outside of North America, discusses his upbringing and how it influences his leadership as chief executive. He is one of the few African-American CEOs in the Fortune 500, and shot to prominence after resigning from a council advising the Trump White House. Frazier discusses the importance of values in leadership and how Merck thinks about R&D and drug prices.

Investigative Journalist, David Dayen, will join us to uncover the hidden monopolies that raise drug prices. And Heather “Digby” Parton will be here to help me recap the big stories from this past week. Subscribe to our podcast to get the full show. Just go to www.rofpodcast.com sign up!

Pharmaceutical start-ups are increasingly using drug patent loopholes to jack up prices on old drugs. It's just one example of the wild west of drug pricing. Unlike Europe and Canada, the US doesn't negotiate the price of drugs or provide caps. Guest host Barbara Bogaev asks whether costs are out of control, and explores what should be done about it.

Tuesday, September 22nd, 2015, 10:24PM Chris Ramirez & Trish Comic Mom http://youtu.be/bOEfJIPjWeY 0:02:00 Comic Mom’s Therapist Falls Asleep 0:04:00 Support Dad's Pressure to be Perfect 0:13:00 Support Dad’s Theoretical Midlife Rebellion 0:20:00 Public High School Bus, Bullies, Jocks & Interracial 0:24:00 Goodnight Universe Word Spreads in Small Town 0:29:00 Proposition Petitions at California Supermarkets 0:32:00 Breastfeeding: Wet Nurse & Tandem Nursing 0:34:00 Outrage with Big Pharma over High Drug Prices 0:38:00 Women Jealous of Other Women’s Looks 0:40:00 Comic Mom’s Coworker Gender Preference 0:47:00 Work Drama & Why Some People Don’t Say Hello 1:04:00 Getting Out of Jury Duty & Bad Liars 1:16:00 Yogisms: Yogi Berra’s Legacy of Paradox 1:30:00 Freeway Rick Ross, CIA & Crack Cocaine 1:40:00 Foo Fighters Concert with Stevie Nicks & Haim 1:47:00 Scott Walker Ends GOP Presidential C 1:51:00 New Muppets Sitcom vs Muppet Babies Cartoon 1:54:00 Rating Comic Mom’s Boys on Comedy & Support